OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 64 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Follow-Up Questions
ORPOF 股票的價格表現如何？
ORPOF 的當前價格為 $0，在上個交易日 decreased 了 0%。
OSE Immunotherapeutics SA 的主要業務主題或行業是什麼？
OSE Immunotherapeutics SA 屬於 Biotechnology 行業，該板塊是 Health Care
OSE Immunotherapeutics SA 的市值是多少？
OSE Immunotherapeutics SA 的當前市值是 $NaN
OSE Immunotherapeutics SA 是買入、賣出還是持有？
據華爾街分析師稱，共有 6 位分析師對 OSE Immunotherapeutics SA 進行了分析師評級，包括 1 位強烈買入，6 位買入，1 位持有，0 位賣出，以及 1 位強烈賣出
